These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7013856)

  • 1. High-dose nitrogen mustard (HN2) with autologous nonfrozen bone marrow transplantation in advanced malignant melanoma. A phase I trial.
    Hartmann DW; Robinson WA; Morton NJ; Mangalik A; Glode LM
    Blut; 1981 Apr; 42(4):209-20. PubMed ID: 7013856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
    Thomas MR; Robinson WA; Glode LM; Dantas ME; Koeppler H; Morton N; Sutherland J
    Am J Clin Oncol; 1982 Dec; 5(6):611-22. PubMed ID: 6762087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of injury after nitrogen mustard (HN2) therapy: the radioiron disappearance rate as a dosimeter.
    Woods AH; O'Bar PR
    Int J Appl Radiat Isot; 1970 Apr; 21(4):213-7. PubMed ID: 4912770
    [No Abstract]   [Full Text] [Related]  

  • 4. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group.
    Wolff SN; Herzig RH; Fay JW; LeMaistre CF; Frei-Lahr D; Lowder J; Bolwell B; Giannone L; Herzig GP
    J Clin Oncol; 1989 Feb; 7(2):245-9. PubMed ID: 2492594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cycloheximide on the bone marrow toxicity of nitrogen mustard.
    Weissberg JB; Herion JC; Walker RI; Palmer JG
    Cancer Res; 1978 Jun; 38(6):1523-7. PubMed ID: 656182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unanticipated side effects from treatment with high-dose mechlorethamine in patients with malignant melanoma.
    Hartmann DW; Robinson WA; Mangalik A; Glode LM; Triebel F
    Cancer Treat Rep; 1981; 65(3-4):327-8. PubMed ID: 7237455
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose chemotherapy with autologous bone marrow support in advanced malignant melanoma.
    Koeppler H; Pflueger KH; Seitz R; Havemann K
    Onkologie; 1989 Dec; 12(6):277-9. PubMed ID: 2696912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma.
    Leff RS; Thompson JM; Johnson DB; Mosley KR; Daly MB; Knight WA; Ruxer RL; Messerschmidt GL
    J Clin Oncol; 1986 Nov; 4(11):1586-91. PubMed ID: 3534154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease.
    Huguley CM; Durant JR; Moores RR; Chan YK; Dorfman RF; Johnson L
    Cancer; 1975 Oct; 36(4):1227-40. PubMed ID: 1175125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease.
    Yahalom J; Gulati S; Shank B; Clarkson B; Fuks Z
    Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):915-22. PubMed ID: 2478511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides.
    Chinn DM; Chow S; Kim YH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):951-8. PubMed ID: 10192339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
    Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
    Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice.
    Cantrell JE; Green D; Schein PS
    Cancer Res; 1986 May; 46(5):2340-3. PubMed ID: 2938728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous bone marrow transplantation and melanoma: a focused review of the literature.
    Fields KK
    Ann Plast Surg; 1992 Jan; 28(1):70-3. PubMed ID: 1642411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of blood and bone marrow stem cells following intense chemotherapy and autologous bone marrow transplantation.
    Thomas MR; Robinson WA; Mughal TI; Morton N; Glode LM
    Oncology; 1986; 43(5):273-7. PubMed ID: 3531952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
    Cornbleet MA; McElwain TJ; Kumar PJ; Filshie J; Selby P; Carter RL; Hedley DW; Clark ML; Millar JL
    Br J Cancer; 1983 Sep; 48(3):329-34. PubMed ID: 6351883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitrogen mustard (mechlorethamine) and UVB photocarcinogenesis: a dose response effect.
    Epstein JH
    J Invest Dermatol; 1984 Nov; 83(5):320-2. PubMed ID: 6491361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.